HLB Life Science Co Ltd
KOSDAQ:067630
Intrinsic Value
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. [ Read More ]
The intrinsic value of one HLB Life Science Co Ltd stock under the Base Case scenario is 2 712.67 KRW. Compared to the current market price of 15 770 KRW, HLB Life Science Co Ltd is Overvalued by 83%.
Valuation Backtest
HLB Life Science Co Ltd
Run backtest to discover the historical profit from buying and selling HLB Life Science Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
HLB Life Science Co Ltd
Current Assets | 147B |
Cash & Short-Term Investments | 77.7B |
Receivables | 14.6B |
Other Current Assets | 54.7B |
Non-Current Assets | 276.5B |
Long-Term Investments | 147.2B |
PP&E | 72.9B |
Intangibles | 55.8B |
Other Non-Current Assets | 554.7m |
Current Liabilities | 135.5B |
Accounts Payable | 5.2B |
Accrued Liabilities | 2.3B |
Short-Term Debt | 10.2B |
Other Current Liabilities | 117.8B |
Non-Current Liabilities | 57.2B |
Long-Term Debt | 51.8B |
Other Non-Current Liabilities | 5.4B |
Earnings Waterfall
HLB Life Science Co Ltd
Revenue
|
98B
KRW
|
Cost of Revenue
|
-98.7B
KRW
|
Gross Profit
|
-748.6m
KRW
|
Operating Expenses
|
-23.8B
KRW
|
Operating Income
|
-24.5B
KRW
|
Other Expenses
|
18.5B
KRW
|
Net Income
|
-6B
KRW
|
Free Cash Flow Analysis
HLB Life Science Co Ltd
Profitability Score
Profitability Due Diligence
HLB Life Science Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
HLB Life Science Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
HLB Life Science Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
HLB Life Science Co Ltd's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
HLB Life Science Co Ltd
Shareholder Return
Price
HLB Life Science Co Ltd
Average Annual Return | 13.82% |
Standard Deviation of Annual Returns | 44.9% |
Max Drawdown | -65% |
Market Capitalization | 1.6T KRW |
Shares Outstanding | 107 552 080 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
Contact
IPO
Employees
Officers
The intrinsic value of one HLB Life Science Co Ltd stock under the Base Case scenario is 2 712.67 KRW.
Compared to the current market price of 15 770 KRW, HLB Life Science Co Ltd is Overvalued by 83%.